Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 42 | 1,555 | 40% |
| 2020 | 24 | 1,214 | 43% |
| 2021 | 33 | 1,271 | 48% |
| 2022 | 23 | 1,129 | 52% |
| 2023 | 22 | 1,000 | 56% |
| 2024 | 17 | 916 | 59% |
| 2025 from claims | – | 926 749–1,088 | 61% |
| 2026 forecast | – | 933 730–1,171 | 62% |
| 2027 forecast | – | 935 693–1,236 | 62% |
| 2028 forecast | – | 936 663–1,293 | 63% |
| 2029 forecast | – | 938 637–1,344 | 64% |
| 2030 forecast | – | 938 615–1,392 | 65% |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 65% of the cases CMS names in North Carolina; 13 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 96% inpatient hospital, 4% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 67 | 3,226−2.7%/yr | −2.7%/yr | 1.4 | 0% | 3,330 in 2030+0.5%/yr |
| Texas | 54 | 3,080−4.9%/yr | −4.9%/yr | 1.4 | 0% | 3,370 in 2030+1.5%/yr |
| Georgia | 20 | 1,108−4.6%/yr | −4.6%/yr | 1.3 | 0% | 1,310 in 2030+2.8%/yr |
| Tennessee | 23 | 1,070−7.3%/yr | −7.3%/yr | 1.5 | 0% | 1,090 in 2030+0.3%/yr |
| Virginia | 28 | 1,070−3.9%/yr | −3.9%/yr | 1.0 | 0% | 1,290 in 2030+3.1%/yr |
| Maryland | 19 | 887+1.4%/yr | +1.4%/yr | 1.0 | 0% | 950 in 2030+1.2%/yr |
| Kentucky | 15 | 796−5.1%/yr | −5.1%/yr | 1.7 | 0% | 760 in 2030−0.8%/yr |
| Oklahoma | 16 | 757−4.9%/yr | −4.9%/yr | 1.5 | 0% | 700 in 2030−1.3%/yr |
| South Carolina | 14 | 710−8.3%/yr | −8.3%/yr | 1.0 | 0% | 840 in 2030+2.9%/yr |
| Louisiana | 17 | 665−8.6%/yr | −8.6%/yr | 1.6 | 0% | 580 in 2030−2.4%/yr |
| Alabama | 13 | 603−11%/yr | −11%/yr | 1.3 | 0% | 600 in 2030−0.2%/yr |
| Arkansas | 13 | 532−8.8%/yr | −8.8%/yr | 1.4 | 0% | 550 in 2030+0.4%/yr |
| Mississippi | 11 | 448−8.8%/yr | −8.8%/yr | 1.2 | 0% | 340 in 2030−4.7%/yr |
| West Virginia | 5 | 402−5.6%/yr | −5.6%/yr | 1.9 | 0% | 380 in 2030−1%/yr |
| Delaware | 10 | 186−2.9%/yr | −2.9%/yr | 1.1 | 0% | 180 in 2030−0.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 55 | 5,158−18%/yr | −18%/yr | 5.41.0× | 66% | 4,610 in 2030−1.9%/yr |
| Peripheral arterial intervention | 34 | 4,853−8.1%/yr | −8.1%/yr | 4.60.7× | 39% | 4,620 in 2030−0.8%/yr |
| Superficial venous ablation | 57 | 4,216−3.9%/yr | −3.9%/yr | 4.00.6× | 97% | 3,890 in 2030−1.3%/yr |
| Thrombectomy, IVC filters & venous stents | 4 | 1,069−0.8%/yr | −0.8%/yr | 1.10.6× | 0% | 1,460 in 2030+5.4%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 449−8.3%/yr | −8.3%/yr | 0.50.9× | 0% | 420 in 2030−1.1%/yr |
Carotid revascularization in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Florida
Boston Scientific leads with 35% of company spending on these surgeons in 2025, −42 pts on 2024.
In 2025, 7 companies reported engagement with North Carolina’s surgeons worth $7,875 in consulting, speaking, meals and travel tied to these products, about $463 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 35301 (rechanneling of artery), commercial plans pay North Carolina’s hospitals a median of $1,188, from $1,188 at the lowest to $1,188 at the highest, across 3 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.